The predictive value of p53, p27Kip1, and α-catenin for progression in superficial bladder carcinoma

被引:24
作者
Schrier, Barthold Ph. [1 ]
Vriesema, Jessica L. J. [1 ]
Witjes, J. Alfred [1 ]
Kiemeney, Lambertus A. L. M. [1 ]
Schalken, Jack A. [1 ]
机构
[1] Radboud Univ Nijmegen, Dept Urol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
关键词
bladder cancer; urothelial cell carcinoma; cell adhesion complex; cell regulatory proteins; p53; prognosis;
D O I
10.1016/j.eururo.2005.12.041
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of the study was to confirm the predictive value of cell cycle regulatory proteins, p53 and p27(kip1), and the cell adhesion complex protein a-catenin, for progression in patients with superficial bladder carcinoma. Methods: Forty-one patients with progression after primary superficial bladder carcinoma were individually matched to patients with nonprogressive superficial bladder carcinoma. Matching was done for sex, age, tumor stage and grade, concomitant carcinoma in situ (CIS), and duration of follow-up. Immunohistochemical analysis of p53, p27(kip1), and alpha-catenin was performed on each primary bladder tumor. Analysis for the p53 mutation was done on 41 bladder tumor samples. Conditional logistic regression analysis was used to establish the prognostic value of immunohistochemical p53, p27(kip1), and alpha-catenin status. Results: The independent odds ratios for progression were 0.3 (95% confidence interval [CI], 0.1-1.2) for high-risk p27(kip1), 3.4 (95%CI, 0.8-15.2) for high-risk p53, and 2.5 (95%CI, 0.6-10.3) for high-risk alpha-catenin. Combinations of different markers had no synergistic effects. Two p53 mutations were found in 21 DNA samples analyzed from nonprogressive tumors (9.5%); 8 of 20 samples (40%) from progressive tumors showed a p53 mutation. The probability of high-risk p53 immunostaining was 5-fold increased in case of mutations in p53. The estimated positive predictive value of high-risk p53 or high-risk a-catenin was about 23%. Conclusions: We confirm that high-risk p53, p53 mutation, and alpha-catenin immunohistochemistry do have an additional prognostic value in primary bladder carcinoma. However, the clinical value of the investigated parameters remains limited. (c) 2005 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 28 条
[1]  
Epstein JI, 2000, AM J SURG PATHOL, V24, P161
[2]   ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE [J].
FINLAY, CA ;
HINDS, PW ;
TAN, TH ;
ELIYAHU, D ;
OREN, M ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :531-539
[3]   Cyclin-dependent kinase inhibitor p27KIP1 is expressed preferentially in early stages of urothelial carcinoma [J].
Franke, KH ;
Miklosi, M ;
Goebell, P ;
Clasen, S ;
Steinhoff, C ;
Anastasiadis, AG ;
Gerharz, CD ;
Schulz, WA .
UROLOGY, 2000, 56 (04) :689-695
[4]   Metastasis markers in bladder cancer: A review of the literature and clinical considerations [J].
Gontero, P ;
Banisadr, S ;
Frea, B ;
Brausi, M .
EUROPEAN UROLOGY, 2004, 46 (03) :296-311
[5]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[6]   P53 IN TUMOR PATHOLOGY - CAN WE TRUST IMMUNOHISTOCHEMISTRY - REVISITED [J].
HALL, PA ;
LANE, DP .
JOURNAL OF PATHOLOGY, 1994, 172 (01) :1-4
[7]  
HENEY NM, 1992, UROL CLIN N AM, V19, P429
[8]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[9]   Stage progression in TA papillary urothelial tumors:: Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy [J].
Holmäng, S ;
Andius, P ;
Hedelin, H ;
Wester, K ;
Busch, C ;
Johansson, SL .
JOURNAL OF UROLOGY, 2001, 165 (04) :1124-1128
[10]   Decreasing of p27Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer [J].
Kamai, T ;
Takagi, K ;
Asami, H ;
Ito, Y ;
Oshima, H ;
Yoshida, KI .
BRITISH JOURNAL OF CANCER, 2001, 84 (09) :1242-1251